| Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
| 06/08/2023 | Gossamer Bio, Inc. | GOSS | Grant | Stock Option (Right to Buy) | 35k | $1.26 | $44.1k | | 06/08/2023 |
| 06/28/2022 | Magenta Therapeutics, Inc. | MGTA | Grant | Stock Option (Right to Buy) | 20k | $1.21 | $24.2k | | 06/28/2022 |
| 06/09/2022 | Gossamer Bio, Inc. | GOSS | Grant | Stock Option (Right to Buy) | 30k | $7.02 | $210.6k | | 06/09/2022 |
| 06/09/2021 | Gossamer Bio, Inc. | GOSS | Grant | Stock Option (Right to Buy) | 23.5k | $8.97 | $210.8k | | 06/09/2021 |
| 06/01/2021 | Magenta Therapeutics, Inc. | MGTA | Grant | Stock Option (Right to Buy) | 18.2k | $12.91 | $234.8k | | 06/01/2021 |
| 05/12/2021 | Larimar Therapeutics, Inc. | ZFGN | Grant | Stock Option (right to buy) | 8.3k | $10.34 | $85.8k | | 05/12/2021 |
| 09/29/2020 | Larimar Therapeutics, Inc. | ZFGN | Grant | Stock Option (right to buy) | 16.6k | $11.90 | $197.5k | | 09/29/2020 |
| 06/17/2020 | Gossamer Bio, Inc. | GOSS | Grant | Stock Option (right to buy) | 23.5k | $12.10 | $284.4k | | 06/17/2020 |
| 06/05/2020 | Magenta Therapeutics, Inc. | MGTA | Grant | Stock Option (Right to Buy) | 18.2k | $9.99 | $181.7k | | 06/05/2020 |
| 06/26/2019 | Larimar Therapeutics, Inc. | ZFGN | Grant | Stock Option (Right to Buy) | 27k | $1.25 | $33.8k | | 06/26/2019 |
| 06/10/2019 | Gossamer Bio, Inc. | GOSS | Grant | Stock Option (right to buy) | 23.5k | $19.54 | $459.2k | | 06/10/2019 |
| 06/07/2019 | Magenta Therapeutics, Inc. | MGTA | Grant | Stock Option (Right to Buy) | 18.2k | $13.40 | $243.7k | | 06/07/2019 |
| 02/12/2019 | Gossamer Bio, Inc. | GOSS | Conversion | Common Stock | 38.1k | $0.00 | $0 | By family trust | 02/12/2019 |
| 02/12/2019 | Gossamer Bio, Inc. | GOSS | Conversion | Series A Preferred Stock | 171.4k | $0.00 | $0 | By family trust | 02/12/2019 |
| 01/24/2019 | Larimar Therapeutics, Inc. | ZFGN | Grant | Stock Option (Right to Buy) | 13.3k | $4.38 | $58.2k | | 01/24/2019 |
| 06/25/2018 | Magenta Therapeutics, Inc. | MGTA | Conversion | Common Stock | 24.5k | $0.00 | $0 | | 06/25/2018 |
| 06/25/2018 | Magenta Therapeutics, Inc. | MGTA | Conversion | Series A Preferred Stock | 33.4k | $0.00 | $0 | | 06/25/2018 |
| 06/25/2018 | Magenta Therapeutics, Inc. | MGTA | Conversion | Series B Preferred Stock | 30k | $0.00 | $0 | | 06/25/2018 |
| 06/06/2018 | Larimar Therapeutics, Inc. | ZFGN | Grant | Stock Option (Right to Buy) | 20k | $6.79 | $135.8k | | 06/06/2018 |
| 03/05/2018 | Juno Therapeutics, Inc. | JUNO | Disposition | Director Stock Option (Right to Buy) | 12k | $23.29 | $279.5k | | 03/05/2018 |
| 01/03/2018 | Larimar Therapeutics, Inc. | ZFGN | Grant | Common Stock | 8.7k | $5.18 | $45k | | 01/03/2018 |
| 06/16/2017 | Juno Therapeutics, Inc. | JUNO | Grant | Stock Option (Right to Buy) | 12k | $23.29 | $279.5k | | 06/16/2017 |
| 02/13/2017 | Larimar Therapeutics, Inc. | ZFGN | Grant | Common Stock | 10.8k | $4.18 | $45k | | 02/13/2017 |
| 04/01/2016 | Larimar Therapeutics, Inc. | ZFGN | Grant | Stock Option (Right to Buy) | 24k | $6.70 | $160.8k | | 04/01/2016 |
| 04/01/2016 | Larimar Therapeutics, Inc. | ZFGN | Grant | Stock Option (Right to Buy) | 3.8k | $6.70 | $25.7k | | 04/01/2016 |
| 04/29/2013 | CELGENE CORP /DE/ | CELG | Grant | Restricted Stock Unit | 5.5k | $0.00 | $0 | | 04/29/2013 |
| 04/29/2013 | CELGENE CORP /DE/ | CELG | Grant | Stock Option (right to buy) | 11.8k | $118.47 | $1.4M | | 04/29/2013 |
| 07/30/2012 | CELGENE CORP /DE/ | CELG | Grant | Stock Option (right to buy) | 8.3k | $69.40 | $577.8k | | 07/30/2012 |